At a glance
ClinicalIndex Comparison RecordN/ACompleted· 150 enrolled
Drug / intervention
Group1:Spiriva® Respimat® +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Cross-sectional Study to Assess the Handling , Patient Satisfaction, and Preference for Inhalation Devices in Patients With Chronic Obstructive Pulmonary Disease (COPD).
In Brief
An observational study evaluating Group1:Spiriva® Respimat® and Group2:Hirobriz®/Oslif®/Onbrez® Breezhaler® for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 150 participants across 15 sites.
Detailed Summary
In COPD the patient's ability to use inhalers correctly and their preference for the inhaler are both important factors in selecting an appropriate treatment for COPD. This is a cross-sectional study where satisfaction, preference and handling of two different devices such as Respimat and Breezhaler will be evaluated by using the validated PASAPQ in COPD patients
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesSpain
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2013
First PostedMar 2013
Primary CompletionMar 2014
TodayJul 2026
First PostedMar 13, 2013
Enrollment StartMar 1, 2013
Primary CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 13.3 years ago
Interventions
Group1:Spiriva® Respimat®device
COPD patients using Respimat®
Group2:Hirobriz®/Oslif®/Onbrez® Breezhaler®device
COPD patients using Breezhaler®®